Teehan B P, Smith L J, Sigler M H, Gilgore G S, Schleifer C R
Am J Clin Nutr. 1978 Oct;31(10):1932-6. doi: 10.1093/ajcn/31.10.1932.
Plasma pyridoxal-5'-phosphate (PLP) was measured by a specific method in 45 stable, chronic hemodialysis patients and 13 normal adults. Despite oral pyridoxine supplements (1 to 5 mg/day) a majority (64%) of patients had low levels. The difference between normals (8.5 +/- 3.7 ng/ml) and dialysis patients (3.6 +/- 3.6 ng/ml) was significant at P less than 0.01. Plasma PLP appeared to decrease with increasing duration of time on dialysis therapy. In vivo clearance studies as well as pre- and postdialysis plasma levels indicated that PLP was not removed by the dialyzer. Mean plasma PLP levels were normal in patients with stable motor nerve conduction velocity and a low transfusion requirement and low in those with decreasing motor nerve conduction velocity or a high transfusion requirement but the difference between the means in each group was not statistically significant. High oral doses of pyridoxine (100 to 200 mg/day) but not low doses (1 to 5 mg/day) restored PLP levels to normal in a majority of patients after 2 weeks.
采用特定方法对45例稳定的慢性血液透析患者和13名正常成年人的血浆吡哆醛-5'-磷酸（PLP）进行了测定。尽管患者口服了吡哆醇补充剂（1至5毫克/天），但大多数（64%）患者的PLP水平仍较低。正常成年人（8.5±3.7纳克/毫升）与透析患者（3.6±3.6纳克/毫升）之间的差异在P<0.01时具有统计学意义。血浆PLP水平似乎随着透析治疗时间的延长而降低。体内清除研究以及透析前后的血浆水平表明，透析器不能清除PLP。运动神经传导速度稳定且输血需求量低的患者，其平均血浆PLP水平正常；而运动神经传导速度降低或输血需求量高的患者，其平均血浆PLP水平较低，但两组患者平均值之间的差异无统计学意义。大多数患者在口服高剂量（100至200毫克/天）而非低剂量（1至5毫克/天）的吡哆醇2周后，PLP水平恢复正常。
